Discuss and debate new evidence and recommendations coming from GOLD strategy 2021 and CTS COPD Guidelines to optimize patient outcomes:

  • Treatment recommendations considering treatable traits and escalation for the right patient at the right time;

  • ICS containing regimens and Pneumonia: new evidence to further weigh benefit vs risk;

  • All-cause mortality and co-morbidities: the complete picture.

About our speakers

Jean Bourbeau, MD, MSc, FRCPC

Dr. Jean Bourbeau is a respirologist, associate professor and the Director of the Research Institute MUHC’s Center for Innovative Medicine, the COPD Clinic and the Pulmonary Rehabilitation Unit at the MUHC Montreal Chest Institute. He has been President of the Canadian Thoracic Society. His work and research on COPD, pulmonary rehabilitation, integrated self-management programs for patients with COPD (‘Living Well with COPD’) have had an impact not only in the field of research, but also in clinical practice at the national and international level.

Bryan Ross, MD, MSc, BSc.H, FRCPC

Dr. Bryan Ross completed his medical school and Internal Medicine residency at the University of Toronto. He completed his Respirology fellowship at the University of Alberta and an additional fellowship in pulmonary rehabilitation and chronic disease management at the Montreal Chest institute (MUHC). He previously completed his undergraduate degree at Queen’s University and his master’s degree in Physiology at McGill University. He has had a longstanding clinical and research interest in respiratory and cardiac physiology and applied exercise science, in pulmonary rehab, and in the management of chronic respiratory disease.